SCHEMBL3974480

SCHEMBL3974480

Cc1cc(Nc2cc3ccc(Br)cc3c(O)n2)n[nH]1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNA2 P20248 1/20 0.45
CDK2 P24941 1/20 0.45
CCNA1 P78396 1/20 0.45
NTRK1 P04629 2/20 0.42
PLK4 O00444 2/20 0.42
PAK4 O96013 2/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
ATM Q13315 1/20 0.42
AURKA O14965 8/20 0.40
AURKB Q96GD4 6/20 0.40
ITK Q08881 1/20 0.40
IGF1R P08069 1/20 0.39
GSK3B P49841 3/20 0.38
GSK3A P49840 2/20 0.38
SRC P12931 2/20 0.38
EIF2AK2 P19525 1/20 0.38
DHODH Q02127 1/20 0.38
JAK2 O60674 2/20 0.37
CYP3A4 P08684 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3972285 0.90 CCNA2 (0.45) CCNA2CDK2CCNA1NTRK1PLK4
SCHEMBL3975930 0.84 PAK4 (0.42) CCNA2CDK2CCNA1NTRK1PLK4
SCHEMBL14520872 0.84 AURKA (0.40) PLK4PAK4AURKAAURKBITK
SCHEMBL3967408 0.79 AURKA (0.41) CCNA2CDK2CCNA1NTRK1PLK4
SCHEMBL3973327 0.78 AURKA (0.41) NPC1RAB9AATMAURKAAURKB
SCHEMBL3961632 0.76 NTRK1 (0.43) CCNA2CDK2CCNA1NTRK1PLK4
SCHEMBL3972216 0.74 SYK (0.46) CCNA2CDK2CCNA1NTRK1PLK4
SCHEMBL3972231 0.73 AURKA (0.41) NTRK1NPC1RAB9AATMAURKA
SCHEMBL14520022 0.73 AURKA (0.41) PLK4PAK4NPC1RAB9AATM
SCHEMBL3971009 0.72 NTRK1 (0.40) CCNA2CDK2CCNA1NTRK1PLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7572809-B2 Isoquinoline aminopyrazole derivatives HOFFMANN-LA ROCHE INC. (US) 2009-08-11 US disclosed
US-7572809-B2 Isoquinoline aminopyrazole derivatives HOFFMANN-LA ROCHE INC. (US) 2009-08-11 US disclosed
US-7572809-B2 Isoquinoline aminopyrazole derivatives HOFFMANN-LA ROCHE INC. (US) 2009-08-11 US disclosed
EP-1966190-A1 ISOQUINOLINE AMINOPYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CANCER F.HOFFMANN-LA ROCHE AG (CH) 2008-09-10 EP disclosed
US-20070179151-A1 Isoquinoline aminopyrazole derivatives F. HOFMANN-LA ROCHE AG (CH) 2007-08-02 US disclosed
US-20070179151-A1 Isoquinoline aminopyrazole derivatives F. HOFMANN-LA ROCHE AG (CH) 2007-08-02 US disclosed
US-20070179151-A1 Isoquinoline aminopyrazole derivatives F. HOFMANN-LA ROCHE AG (CH) 2007-08-02 US disclosed
WO-2007071348-A1 ISOQUINOLINE AMINOPYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2007-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179151-A1 Isoquinoline aminopyrazole derivatives CYP3A5, CYP3A43, CYP3A4 CCNA2 3336/4885CDK2 458/4885CCNA1 2681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.